Abstract
Glycogen synthesis is normally absent in neurons. However, inclusion bodies resembling abnormal glycogen accumulate in several neurological diseases, particularly in progressive myoclonus epilepsy or Lafora disease. We show here that mouse neurons have the enzymatic machinery for synthesizing glycogen, but that it is suppressed by retention of muscle glycogen synthase (MGS) in the phosphorylated, inactive state. This suppression was further ensured by a complex of laforin and malin, which are the two proteins whose mutations cause Lafora disease. The laforin-malin complex caused proteasome-dependent degradation both of the adaptor protein targeting to glycogen, PTG, which brings protein phosphatase 1 to MGS for activation, and of MGS itself. Enforced expression of PTG led to glycogen deposition in neurons and caused apoptosis. Therefore, the malin-laforin complex ensures a blockade of neuronal glycogen synthesis even under intense glycogenic conditions. Here we explain the formation of polyglucosan inclusions in Lafora disease by demonstrating a crucial role for laforin and malin in glycogen synthesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnn1998/MediaObjects/41593_2007_Article_BFnn1998_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnn1998/MediaObjects/41593_2007_Article_BFnn1998_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnn1998/MediaObjects/41593_2007_Article_BFnn1998_Fig3_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnn1998/MediaObjects/41593_2007_Article_BFnn1998_Fig4_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnn1998/MediaObjects/41593_2007_Article_BFnn1998_Fig5_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnn1998/MediaObjects/41593_2007_Article_BFnn1998_Fig6_HTML.jpg)
Similar content being viewed by others
References
Brown, A.M. Brain glycogen re-awakened. J. Neurochem. 89, 537–552 (2004).
Cavanagh, J.B. Corpora-amylacea and the family of polyglucosan diseases. Brain Res. Brain Res. Rev. 29, 265–295 (1999).
Berkovic, S.F., Andermann, F., Carpenter, S. & Wolfe, L.S. Progressive myoclonus epilepsies: specific causes and diagnosis. N. Engl. J. Med. 315, 296–305 (1986).
Lafora, G.R. Über das corkommen amyloider körperchen im innern der ganglienzellen; zugliech ein zum studium der amyloiden substanz im nervensystem. Virchows Arch. Pathol. Anat. 205, 294–303 (1911).
Lafora, G.R. & Glueck, B. Beitrag zur histogpathologie der myoklonischen epilepsie. Z. Gesamte Neurol. Psychiatr. 6, 1–14 (1911).
Collins, G.H., Cowden, R.R. & Nevis, A.H. Myoclonus epilepsy with Lafora bodies. An ultrastructural and cytochemical study. Arch. Pathol. 86, 239–254 (1968).
Sakai, M., Austin, J., Witmer, F. & Trueb, L. Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20, 160–176 (1970).
Acharya, J.N., Satishchandra, P. & Shankar, S.K. Familial progressive myoclonus epilepsy: clinical and electrophysiologic observations. Epilepsia 36, 429–434 (1995).
Berkovic, S.F., Cochius, J., Andermann, E. & Andermann, F. Progressive myoclonus epilepsies: clinical and genetic aspects. Epilepsia 34 (Suppl 3): S19–S30 (1993).
Kobayashi, K., Iyoda, K., Ohtsuka, Y., Ohtahara, S. & Yamada, M. Longitudinal clinicoelectrophysiologic study of a case of Lafora disease proven by skin biopsy. Epilepsia 31, 194–201 (1990).
Minassian, B.A. Lafora's disease: towards a clinical, pathologic and molecular synthesis. Pediatr. Neurol. 25, 21–29 (2001).
Shahwan, A., Farrell, M. & Delanty, N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 4, 239–248 (2005).
Van Heycop Ten Ham, M.W. Lafora disease, a form of progressive myoclonues epilepsy. Handb. Clin. Neurol. 15, 382–422 (1974).
Minassian, B.A. et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 20, 171–174 (1998).
Minassian, B.A. et al. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 55, 341–346 (2000).
Serratosa, J.M. et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum. Mol. Genet. 8, 345–352 (1999).
Wang, J., Stuckey, J.A., Wishart, M.J. & Dixon, J.E. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J. Biol. Chem. 277, 2377–2380 (2002).
Ganesh, S., Puri, R., Singh, S., Mittal, S. & Dubey, D. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J. Hum. Genet. 51, 1–8 (2006).
Chan, E.M. et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 35, 125–127 (2003).
Gentry, M.S., Worby, C.A. & Dixon, J.E. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl. Acad. Sci. USA 102, 8501–8506 (2005).
Ferrer, J.C. et al. Control of glycogen deposition. FEBS Lett. 546, 127–132 (2003).
Gomis, R.R., Cid, E., Garcia-Rocha, M., Ferrer, J.C. & Guinovart, J.J. Liver glycogen synthase but not the muscle isoform differentiates between glucose 6-phosphate produced by glucokinase or hexokinase. J. Biol. Chem. 277, 23246–23252 (2002).
Skurat, A.V., Dietrich, A.D. & Roach, P.J. Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites. Diabetes 49, 1096–1100 (2000).
Ferrer, J.C., Baque, S. & Guinovart, J.J. Muscle glycogen synthase translocates from the cell nucleus to the cystosol in response to glucose. FEBS Lett. 415, 249–252 (1997).
Cid, E., Cifuentes, D., Baque, S., Ferrer, J.C. & Guinovart, J.J. Determinants of the nucleocytoplasmic shuttling of muscle glycogen synthase. FEBS J. 272, 3197–3213 (2005).
Skurat, A.V., Wang, Y. & Roach, P.J. Rabbit skeletal muscle glycogen synthase expressed in COS cells. Identification of regulatory phosphorylation sites. J. Biol. Chem. 269, 25534–25542 (1994).
MacAulay, K. et al. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur. J. Biochem. 270, 3829–3838 (2003).
Printen, J.A., Brady, M.J. & Saltiel, A.R. PTG, a protein phosphatase 1–binding protein with a role in glycogen metabolism. Science 275, 1475–1478 (1997).
Fong, N.M. et al. Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism. J. Biol. Chem. 275, 35034–35039 (2000).
Berman, H.K., O'Doherty, R.M., Anderson, P. & Newgard, C.B. Overexpression of protein targeting to glycogen (PTG) in rat hepatocytes causes profound activation of glycogen synthesis independent of normal hormone- and substrate-mediated regulatory mechanisms. J. Biol. Chem. 273, 26421–26425 (1998).
Fernandez-Sanchez, M.E. et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase 1 that enhances glycogen accumulation. Hum. Mol. Genet. 12, 3161–3171 (2003).
Allaman, I., Pellerin, L. & Magistretti, P.J. Protein targeting to glycogen mRNA expression is stimulated by noradrenaline in mouse cortical astrocytes. Glia 30, 382–391 (2000).
Schlamowitz, M. On the nature of rabbit liver glycogen. II. Iodine absorption spectrum. J. Biol. Chem. 190, 519–527 (1951).
Lee, D.H. & Goldberg, A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397–403 (1998).
Villar-Palasi, C. & Guinovart, J.J. The role of glucose-6-phosphate in the control of glycogen synthase. FASEB J. 11, 544–558 (1997).
Simo, S. et al. Reelin induces the detachment of postnatal subventricular zone cells and the expression of the Egr-1 through Erk1/2 activation. Cereb. Cortex 17, 294–303 (2007).
Seoane, J. et al. Glucose-6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. J. Biol. Chem. 271, 23756–23760 (1996).
Becker, T.C. et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43 (Pt A): 161–189 (1994).
McGrory, W.J., Bautista, D.S. & Graham, F.L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163, 614–617 (1988).
Hojlund, K. et al. Increased phosphorylation of skeletal muscle glycogen synthase at NH2-terminal sites during physiological hyperinsulinemia in type 2 diabetes. Diabetes 52, 1393–1402 (2003).
Baba, O. [Production of monoclonal antibody that recognizes glycogen and its application for immunohistochemistry.]. Kokubyo Gakkai Zasshi. 60, 264–287 (1993).
Chan, T.M. & Exton, J.H. A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal. Biochem. 71, 96–105 (1976).
Lang, G. & Michal, G. d-glucose-6-phosphate and d-Fructose-6-phosphate. in Methods of Enzymatic Analysis (ed. Bergmeyer, H. U.) 1238–1242 (Academic Press, New York, 1974).
Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976).
Thomas, J.A., Schlender, K.K. & Larner, J. A rapid filter paper assay for UDPglucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. Anal. Biochem. 25, 486–499 (1968).
Guinovart, J.J. et al. Glycogen synthase: a new activity ratio assay expressing a high sensitivity to the phosphorylation state. FEBS Lett. 106, 284–288 (1979).
Acknowledgements
We thank J. Massagué for providing a critical review of the manuscript, P. Sanz and J.M. Serratosa for their advice, A. Adrover and E. Veza for their technical support, and T. Yates for correcting the manuscript. We also thank R.R. Gomis for the AdCMV-PTG virus, O. Baba for the monoclonal antibody to glycogen and D.G. Hardy for the gift of the PGSser7/10 antibody. This study was supported by grants from the Fundació La Caixa, Fundació La Marató de TV3, Fundación Marcelino Botín, the Spanish Ministry of Education and Science (SAF2005-00913; BFU2005-02253) and the Instituto de Salud Carlos III (CIBER-ER; RD06/0015/0030).
Author information
Authors and Affiliations
Contributions
D.V. conducted most of the experiments, data analysis and interpretation. S.R. generated the AdCMV-laf, AdCMV-malin and AdCMV-malinD146N recombinant adenoviruses. D.C. carried out the RT-PCR experiments. L.P. contributed to the primary neuron cultures and the apoptosis assays. J.V. carried out the analysis of glycogen branching. S.R., D.C. and J.V. also contributed to other experiments. B.G.-F., O.C.-G., E.F.-S. and I.M.-F. generated the monoclonal laforin antibody, pCINeo-Laforin vector and pcDNA3-Malin-HA vector. J.D. supervised several experiments and the data analysis, and contributed to writing the manuscript. M.G.-R. supervised the western blot and immunofluorescence experiments. E.S. contributed with his knowledge of the nervous system. S.R.d.C. and J.J.G. planned and supervised the project, co-wrote the manuscript and contributed to every aspect of the project.
Corresponding authors
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–3 and Methods (PDF 7132 kb)
Rights and permissions
About this article
Cite this article
Vilchez, D., Ros, S., Cifuentes, D. et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10, 1407–1413 (2007). https://doi.org/10.1038/nn1998
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn1998